1. Cost-Effectiveness Acceptability Curves Revisited

   • Maiwenn J. Al

   Practical Application 14 December 2012 Pages: 93 - 100

   

2. Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization

   • Dawn Craig
   • Stephen Rice
   • Nerys Woolacott

   Review Article 23 January 2013 Pages: 101 - 110

3. Acknowledging Patient Heterogeneity in Economic Evaluation

   • Janneke P. C. Grutters
   • Mark Sculpher
   • Manuela A. Joore

   Systematic Review 04 January 2013 Pages: 111 - 123

   

4. A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination

   • Thomas D. Szucs
   • Alena M. Pfeil

   Systematic Review 19 January 2013 Pages: 125 - 136

   

5. When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?

   • Louise Longworth
   • JiHee Youn
   • Karl Claxton

   Systematic Review Open access 04 January 2013 Pages: 137 - 149

6. Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling

   • Yumi Asukai
   • Michael Baldwin
   • David Price

   Original Research Article Open access 04 January 2013 Pages: 151 - 161

   

7. Valuing Benefits to Inform a Clinical Trial in Pharmacy

   • Michela Tinelli
   • Mandy Ryan
   • Anthony Scott

   Original Research Article 15 December 2012 Pages: 163 - 171

8. Comparing Subsidized Access to Medicines Across Payer Systems

   • Michael Wonder
   • Richard Milne

   Correspondence 08 December 2012 Pages: 173 - 174

9. The Authors’ Reply to Wonder and Milne: “Comparing Subsidized Access to Medicines Across Payer Systems”

   • Rajan Ragupathy
   • Katri Aaltonen
   • David Reith

   Correspondence 15 December 2012 Pages: 175 - 176